Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs)

Journal of Pharmaceutical and Biomedical Analysis

Volumn 48, Issue 3, 2008, Pages 497-507

  Elder, D P ^a   Lipczynski, A M ^b   Teasdale, A ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Active pharmaceutical ingredients; Alkyl and benzyl halides; Potential genotoxic impurities; Review; Trace analysis

Indexed keywords

ALKYL GROUP; ALKYLATING AGENT; ALMOKALANT; AMIODARONE; ATENOLOL; AZASETRON; BENZYL HALIDE; BETA LACTAM; BROMAZEPAM; CARMUSTINE; CLINDAMYCIN; DILTIAZEM; FAMOTIDINE; FENTANYL CITRATE; FOLIC ACID; HALOTHANE; IFOSFAMIDE; INDORAMIN; ISOFLURANE; LOFEPRAMINE; LOMUSTINE; LOTEPREDNOL ETABONATE; MELPHALAN; METRIFONATE; ORGANOHALOGEN DERIVATIVE; SULFONIC ACID DERIVATIVE; TOLNAFTATE; TRAZODONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANALYTIC METHOD; CAPILLARY ZONE ELECTROPHORESIS; CHROMATOGRAPHY; DRUG IMPURITY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PATIENT SAFETY; PRIORITY JOURNAL; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SYNTHESIS; THIN LAYER CHROMATOGRAPHY;

ALKYLATING AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CONTAMINATION; HALOGENS; MUTAGENS; PHARMACEUTICAL PREPARATIONS; SALTS;

EID: 53349098836     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.06.009     Document Type: Review

References (44)

1. Elder D.P., Teasdale A., and Lipczynski A.M. J. Pharm. Biomed. Anal. 46 (2008) 1-8
2. Jacobson-Kram D., and McGovern T. Adv. Drug Deliv. Rev. 59 (2007) 38-42
3. Muller L., Mauthe R.J., Riley C.M., Andino M.M., de Antonis D., Beels C., DeGeorge J., De Knaep A.G.M., Ellison D., Fagerland J.A., Frank R., Fritschel B., Galloway S., Harpur E., Humfrey C.D.N., Jacks A.S., Jagota N., Mackinnon J., Mohan G., Ness D.K., O'Donovan M.R., Smith M.D., Vudathala G., and Yotti L. Regul. Toxicol. Pharmacol. 44 (2006) 198-211
4. Friscia O., Pulci R., Fassio F., and Comelli R. J. Environ. Pathol. Toxicol. Oncol. 13 (1994) 89-110
5. McGovern T., and Jacobson-Kram D. Trends Anal. Chem. 25 (2006) 790-795
6. Dobo K.L., Greene N., Cyr M.O., Caron S., and Ku W.W. Regul. Toxicol. Pharmacol. 44 (2006) 282-293
7. ICH Q9, Quality Risk Management, June 2006, http://www.ICH.org/.
8. Skett P. In: Smith R.J., and Webb M.L. (Eds). Low Level Measurement of Potent Toxins Analysis of Drug Impurities (2007), Blackwell Publishing, Oxford 82-123
9. Ellison G.K. Pharmaceutical Analysis Science Group (PASG) Autumn Meeting. Milton Keynes, UK, October 02 (2006)
10. Wan Y. Yaowu Fenxi Zazhi 24 (2004) 293-295
11. Li H., and Sluggett G.W. J. Pharm. Biomed. Anal. 39 (2005) 486-494
12. Langelaan F.C.G.M., and Nielsen M.W.F. Int. J. Environ. Anal. Chem. 36 (2002) 27-34
13. Knapp D.R. Handbook of Chemical Derivatisation Reactions (1979), John Wiley and Sons, New York pp. 1-24
14. Frost R.P., Hussain M.S., and Raghani A.R. J. Sep. Sci. 26 (2003) 1097-1103
15. Klick S. J. Pharm. Biomed. Anal. 13 (1995) 563-566
16. Klick S. J. Chromatogr. A 689 (1995) 69-76
17. Lee C.B., Hubert M., Nguyen Van Dua C., Meter D., and Krstulovic A.M. Analyst 125 (2000) 1255-1259
18. Clarke C. Development and Validation of LC/MS Methods That Demonstrate the Control of Toxic Impurities at the Low ppm Levels in Drug Substance, Proceedings of the International Separations Conference (2004)
19. S. Hamilton, A. Ray, K. Dennis, Unpublished Work (2003) through P. Skett [8].
20. Huybrechts T. Genotoxic Impurities 2007. Hilton Prague, September 24th (2007)
21. Orwa J.A., Vandenbempt K., Depuydt S., Roets E., and Hoogmartens J. J. Pharm. Biomed. Anal. 20 (1999) 745-752
22. Hussain S., Khalid S., Nagaraju N., and Rao R.N. J. Chromatogr. A 743 (1996) 328-334
23. Görög S., Balogh G., Csehi A., Csizér S., Gazdag M., Halmos Z.S., Hegedüs B., Herényi B., Horvárth P., and Laukó A. J. Pharm. Biomed. Anal. 11 (1993) 1219-1226
24. Helali N., Dargouth F., and Monser L. Chromatographia 60 (2004) 455-460
25. Yasueda S.I., Higashiyama M., Shirasaki Y., Inada K., and Ohtori A. J. Pharm. Biomed. Anal. 36 (2004) 309-316
26. Brightman K., Finlay G., Jarvis I., Knowlton T., and Manktelow C.T. J. Pharm. Biomed. Anal. 20 (1999) 439-447
27. Rao D.S., Geetha S., Srinivasu M.K., and Reddy G.O. J. Pharm. Biomed. Anal. 26 (2001) 629-636
28. Lacroix P.M., Gragham S.J., and Lovering E.G. J. Pharm. Biomed. Anal. 9 (1991) 817-822
29. Valvo L., Alimenti R., Alimonti S., Raimondi S., Foglietta F., and Campana F. Pharm. Biomed. Anal. 15 (1997) 989-996
30. Singh A., Rao B.M., Deshpande G.R., Sangaraju S., Srinivasu M.K., Devi M.L., Satyanarayana P.V.V., and Chandrasekhar K.B. Chromatographia 65 (2007) 191-196
31. Sass S., and Stutz M.H. J. Chromatogr. 213 (1981) 173-176
32. Hansen S.H., and Sheribah Z.A. J. Pharm. Biomed. Anal. 39 (2005) 322-327
33. Alzaga R., Ryan R.W., Taylor/Worth K., Lipczynski A.M., Szucs R., and Sandra P. J. Pharm. Biomed. Anal. 45 (2007) 472-479
34. Lacroix P.M., Curran N.M., Sy W./W., Gorecki D.K.J., Thibalaut P., and Blay P.K.S. J. AOAC Int. 77 (1994) 1447-1453
35. Vaidya V.V., Khanolkar M., and Gadre J.N. Indian Drugs 37 (2000) 521-523
36. Famotidine Monograph, British Pharmacopeia (2007), The Stationery Office on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA), London, pp. 857-860; Ph Eur Monograph 1012, European Pharmacopoeia (2005) 5th ed., Council of Europe, Strasbourg, pp. 1575-1576.
37. Famotidine, Famotidine Tablets and Famotidine for Oral Suspension Official Monographs; The United States Pharmacopeia (2006) 29th ed. United States Pharmacopeial Convention, Rockville, MD, pp. 881-884.
38. Lambropoulis J., Spanos G.A., Lazaridis N.V., Ingallinera T.S., and Rodriguez V.K. J. Pharm. Biomed. Anal. 20 (1999) 705-716
39. Fentanyl and Fentanyl Citrate Monographs, British Pharmacopeia (2007), The Stationery Office on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA), London, pp. 843-844; Ph Eur Monographs 1210 and 1103, European Pharmacopoeia (2005) 5th ed., Council of Europe, Strasbourg, pp. 1584-1586.
40. Fentanyl Citrate and Fentanyl Citrate Injection Official Monographs, The United States Pharmacopeia (2006) 29th ed., United States Pharmacopeial Convention, Rockville, MD, p. 894.
41. Guideline on the Limits of Genotoxic Impurities, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, London, June 28, 2006. (CPMP/SWP/5199/02, EMEA/CHMP/QWP/251344/2006).
42. Potentially Genotoxic Impurities and European Pharmacopeia Monographs, Summary and Conclusions of Meeting Held at the EDQM on 4th July 2007, European Directorate for the Quality of Medicines and Healthcare, European Pharmacopeia Commission, PA/PH/SG (07) 52 Com, Strasbourg, November 2007.
43. Impact the Future of Pharmacopeial Standards. USP Annual Scientific Meeting 2006, Session IV: Impurities in Drug Substances and Products. Genotoxic Impurities. September 29th 2006, Marriott Denver City Center, Denver, Colorado.
44. Questions and Answers on [41], CHMP Safety Working Party (SWP). European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use, London, January 2008. (EMEA/CHMP/SWP/431994/2007).